0001104659-22-023770.txt : 20220215 0001104659-22-023770.hdr.sgml : 20220215 20220215160148 ACCESSION NUMBER: 0001104659-22-023770 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210716 FILED AS OF DATE: 20220215 DATE AS OF CHANGE: 20220215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Altarac David CENTRAL INDEX KEY: 0001792615 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38670 FILM NUMBER: 22639126 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001724344 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824592913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 810-0120 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Entasis Therapeutics Ltd DATE OF NAME CHANGE: 20171204 4 1 tm226724d3_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-07-16 0 0001724344 Entasis Therapeutics Holdings Inc. ETTX 0001792615 Altarac David C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE WALTHAM MA 02451 0 1 0 0 Chief Medical Officer Employee Stock Option (Right to Buy) 5.70 2021-07-16 4 D 0 120000 D 2029-11-03 Common Stock 120000 0 D Employee Stock Option (Right to Buy) 2.44 2021-07-16 4 A 0 92.307 A 2031-07-15 Common Stock 92307 92307 D The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on November 4, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 120,000 shares of issuer's common stock granted to the Reporting Person on November 4, 2019. In exchange, the Reporting Person received a replacement option for 92,307 shares of issuer's common stock, having an exercise price of $2.44 per share. Sixty-seven percent (67%) of this award will vest on July 16, 2022, and one-sixteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date. Elizabeth M. Keiley as Attorney-in-Fact for David Altarac 2022-02-14